Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2020
Reporting Period: Specific event date of November 12, 2020, relating to an underwritten public offering closing on November 17, 2020.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data disclosed relates to a specific transaction fee:
- Transaction Fee Paid: Approximately $0.8 million.
- Shares Purchased by Avista Funds: 4,272,657 shares of Class A Common Stock.
- Total Offering Size: 19,916,708 shares of Class A Common Stock.
Material Changes
The filing discloses the entry into a Material Definitive Agreement (Item 1.01) on November 12, 2020. Organogenesis Holdings Inc. entered into a Fee Letter Agreement with Avista Capital Partners IV, L.P., Avista Capital Partners (Offshore) IV, L.P., and Avista Capital Holdings, L.P. (collectively, the "Avista Funds" and "Management Company").
Under this agreement, the Company agreed to pay the Management Company a fee equal to the portion of aggregate gross proceeds from Investments sold to the Avista Funds, multiplied by the underwriters' discount or spread rate. This fee structure was implemented because underwriters waived their discount on the portion of the offering sold to the Avista Funds.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of the Fee Letter Agreement in connection with the Company's Registration Statement on Form S-1 (File No. 333-249531). The agreement applies to Covered Offerings made before December 31, 2020.
Risks and Contingencies: The filing notes that no fee is payable if the Avista Funds do not participate in a Covered Offering. The description of the agreement is qualified in its entirety by reference to the full text of the Letter Agreement filed as Exhibit 10.1.
Unusual Items: The filing does not disclose unusual items outside of the specific fee arrangement described above.
Investor Verification Checklist
- Verify the total gross proceeds of the November 17, 2020 offering to contextualize the $0.8 million fee payment.
- Review the full text of the Fee Letter Agreement (Exhibit 10.1) for additional covenants or conditions not summarized in the 8-K.
- Confirm the final underwriting discount rate applied to the non-Avista portion of the offering to validate the fee calculation methodology.
- Check subsequent filings for any additional "Covered Offerings" made before December 31, 2020, which could trigger further fee payments.